Scarica l'app Stockscreener
112.77
0.19%
-0.22
Pre-mercato:
112.94
0.17
+0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences’ Strategic Expansion in HIV Prevention and Global Access: Assessing Long-Term Investment Potential - AInvest
Gilead Sciences advances HIV prevention with new US partnership - Yahoo Finance
Gilead breaks ground on AI-enabled US manufacturing hub - MarketScreener
Momentum divergence signals in Gilead Sciences Inc. chartWeekly Trade Analysis & Risk Controlled Daily Trade Plans - Newser
Stock Analysis | Gilead Sciences OutlookA Strong Technical Picture with Mixed Analyst Signals - AInvest
What earnings revisions data tells us about Gilead Sciences Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - Newser
Gilead joins U.S. efforts in expanding access to new HIV drug in low-income nations - Seeking Alpha
US plans to bring Gilead HIV drug to market in high-burden HIV countries - Reuters
Gilead partners with PEPFAR to expand HIV prevention access - Investing.com
U.S. to bring Gilead’s HIV drug lenacapavir to high-burden countries - Investing.com
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire
US Plans to Bring Gilead HIV Drug to Market in High-Burden HIV Countries - U.S. News & World Report
Gilead Sciences to Offer Lenacapavir at Cost for Global HIV Prevention - Devdiscourse
Gilead at Wells Fargo Conference: Strategic Growth and Challenges - Investing.com
Gilead Sciences breaks ground on new manufacturing hub - The Pharma Letter
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire Inc.
'I can't wait to see where we go': Gilead launches $32 billion U.S. investment with new Foster City building - The Business Journals
Gilead Breaks Ground on Pharmaceutical Development & Manufacturing Technical Development Center - Contract Pharma
Gilead Sciences describes new Mpro inhibitors for SARS-CoV-2 - BioWorld MedTech
Gilead begins construction of new manufacturing centre in US - World Pharmaceutical Frontiers
Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Business Wire
Gilead, Amgen kick off facility investments in US - pharmaphorum
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Bakersfield.com
Gilead unveils new California manufacturing site, part of $32B US investment - FirstWord Pharma
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy - BioSpace
Is Gilead Sciences Stock Underperforming the Nasdaq? - MSN
Is Gilead Sciences Stock Underperforming The Nasdaq? - Barchart.com
Gilead breaks ground on AI-enabled biopharma hub at Foster City headquarters - KRON4
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Gilead Sciences’ Strategic Position in the Evolving Biopharma Landscape - AInvest
Gilead breaks ground on Foster City manufacturing hub as $32B US investment plan plays out - Fierce Pharma
Gilead at Cantor Global Healthcare Conference: Strategic Focus on Innovation - Investing.com
Gilead Sciences' $32 Billion U.S. Expansion and Its Implications for Biopharma Innovation and Stock Value - AInvest
Gilead Sciences $32B Investment in US Pharma ManufacturingNews and Statistics - IndexBox
Gilead Sciences’ $32 Billion U.S. Expansion and Its Implications for Biopharma Leadership - AInvest
4 Questions on Gilead’s New Technical Development Center with Stacey Ma & Jamie Moore - Gilead Sciences
Gilead Sciences Breaks Ground on New Manufacturing Center at California HQ - MarketScreener
Gilead's $32 Billion US Manufacturing Expansion: A Strategic Catalyst for Long-Term Shareholder Value - AInvest
Gilead breaks ground on manufacturing development site at California HQ - Seeking Alpha
Gilead breaks ground on new Bay Area facility as part of $32 billion investment By Investing.com - Investing.com
Gilead Sciences' $32 Billion U.S. Investment: A Strategic Catalyst for Biopharma Innovation and Shareholder Value - AInvest
Gilead Sciences breaks ground on new manufacturing facility in Foster City - StreetInsider
$43B Economic Impact: Gilead Sciences Launches Massive U.S. Manufacturing Expansion with AI-Enabled Hub - Stock Titan
Intraday pattern recognizer results for Gilead Sciences Inc.Market Risk Analysis & Growth Focused Entry Reports - Newser
Will Gilead Sciences Inc. stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
How hedge fund analytics apply to Gilead Sciences Inc. stockTake Profit & Growth Oriented Trade Recommendations - Newser
Using RSI to spot recovery in Gilead Sciences Inc.2025 Retail Activity & High Return Stock Watch Alerts - Newser
What to expect from Gilead Sciences Inc. in the next 30 daysQuarterly Profit Review & Low Risk Entry Point Guides - Newser
Gilead's $0.5B Volume Ranks 215th as Q2 Sales Climb and Yeztugo Approval Signals Long-Term Innovation - AInvest
Market Trends: Can Gilead Sciences Inc. grow without external funding2025 Winners & Losers & Consistent Income Trade Ideas - khodrobank.com
Gilead is said to seek price hikes for HIV meds supplied for state AIDS drug programs - Seeking Alpha
What Do Analysts Think About Gilead Sciences (GILD)? - MSN
Gilead Sciences - Fierce Pharma
How do insiders feel about Gilead Sciences Inc.Earnings Risk Summary & Smart Swing Trading Techniques - khodrobank.com
Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales - Seeking Alpha
Visual trend scoring systems applied to Gilead Sciences Inc.July 2025 Analyst Calls & Short-Term High Return Ideas - Newser
Gilead Sciences, Inc. (GILD) Wins FDA Approval for World’s First Twice-Yearly HIV Preventive Therapy - Yahoo Finance
Forecasting Gilead Sciences Inc. price range with options dataTake Profit & Real-Time Chart Breakout Alerts - Newser
Gilead Sciences Inc. Recovery Likely Here’s What Data Shows getLinesFromResByArray error: size == 0 - thegnnews.com
Gilead Sciences’ SWOT analysis: HIV giant faces challenges, oncology promise - Investing.com
Is Gilead Sciences Inc. currently under institutional pressureTrade Entry Summary & Target Return Focused Picks - خودرو بانک
1.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):